2020-07-01| PartnerAsia-Pacific

The Most Effective, Efficient and Targeted Business Partnering Platform Available!

by GeneOnline
Share To

With interest building and with the biggest names in biotech already signed up, BIO Asia – Taiwan 2020 Online + Live, July 22-26, is expecting to host thousands of partnering meetings through the online BIO One-on-One Partnering™ system. This is your best chance to connect with the widest range of quality bioindustry contacts in Asia and beyond. As an online event, the system is open for both scheduling and partnering 24 hours a day over the five days of the conference. There’s no travel, no jetlag, just plenty of opportunities! Sign up now to participate in this world-renowned partnering platform, and start filling up your meeting calendar!

Join Free Webinar Training Course

Join our webinar and learn how to take full advantage of the great new features of the BIO One-on-One Partnering™ system, including:

• Self-schedule meetings during 5 full days of partnering from July 22-26, 2020.

• View your partnering calendar in your own time zone.

• Input the meeting location of your choice, with the flexibility to choose whatever virtual meeting option you prefer.

• A preview of BIO Asia–Taiwan, best practices for partnering, and much more.

Please visit the event website for the complete list, updated regularly.

© All rights reserved. Collaborate with us:
Related Post
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
BIO Asia-Taiwan 2022: Top iPS Cell Technologies at Affordable Prices – Keynote by Nobel Laureate Shinya Yamanaka
Reinvigorating the Asian Biomedical Ecosystem With BIO Asia-Taiwan 2022
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
Ways to Reduce Carbon Emission in Cement Manufacturing
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
Scroll to Top